Europe Next Generation Sequencing Ngs Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2023 –2029 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | USD 100.35 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
|
Europe Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands and Rest of Europe) Industry Trends & Forecast to 2029.
Market Analysis and Insights: Europe Next Generation Sequencing (NGS) Market
Europe next generation sequencing (NGS) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 15.7% in the forecast period of 2022 to 2029 and is expected to reach USD 8,733.08 million by 2029. Increasing research activities over next generation sequencing act as driver for the next generation sequencing (NGS) market growth.
High-throughput sequencing, most widely regarded as the "next-generation" sequencing (NGS), is now integrated into routine clinical practice due to the numerous technical and functional developments, while early protocols relied on samples harvested outside of typical workflows in clinical pathology, standard formalin-fixed, paraffin-embedded specimens which can be used more regularly as starting material for NGS. In addition, protocols are being amassed for the analysis and interpretation of NGS data, as well as knowledge bases, allowing clinicians to act more easily on genomic information at the patient care point. The presence of wide range of products of the next generation sequencing used in the diagnosis of chronic diseases is satisfying the need of the healthcare facilities. The increased technological advancement leads to development of highly efficient next generation sequencing (NGS) in the market.
Major factors driving the growth of next generation sequencing (NGS) market are use of next generation sequencing in drug development and wide portfolio offered by major player and the factor which hampers the growth of the next generation sequencing (NGS) market includes high cost of next generation sequencing products and product recall.
The next generation sequencing (NGS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the next generation sequencing (NGS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Next Generation Sequencing (NGS) Market Scope and Market Size
The next generation sequencing (NGS) market is segmented on basis of product, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Europe next generation sequencing (NGS) market is segmented into instrument, consumables, and services. In 2022, the instrument segment is expected to dominate the Europe next generation sequencing (NGS) market as the instruments as the presence of wide instrument portfolio available for the European countries and this is also the major segment contributing to the revenue.
- On the basis of application, the Europe next generation sequencing (NGS) market is segmented into diagnostic, drug discovery, biomarker discovery, precision medicine, agriculture and animal research. In 2022, the diagnostic segment is expected to dominate Europe next generation sequencing (NGS) market due to the fact that clinical laboratories and laboratories are using NGS for routine diagnosis of various disease because it has the potential to deliver precise test result and provide excellent treatment regime.
- On the basis of end user, the Europe next generation sequencing (NGS) market is segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies. In 2022, research center and academic & government institutes is expected to dominate the Europe next generation sequencing (NGS) market as the European countries are known to have advance research institutes which are constantly working on NGS with collaboration with Pharma companies,
Next Generation Sequencing (NGS) Market Country Level Analysis
The next generation sequencing (NGS) market is analyzed and market size information is provided by the country, product, application and end user as referenced above.
The countries covered in the next generation sequencing (NGS) market report are the U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Austria, Ireland, and Rest of Europe.
Research centers and academic & government institutes segment in Germany of European region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of NGS in these centers where the ground level research is performed.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Next Generation Sequencing (NGS) Treatment, is Boosting the Market Growth of Next Generation Sequencing (NGS) Market
The next generation sequencing (NGS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Next Generation Sequencing (NGS) Market Share Analysis
Next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induce next generation sequencing (NGS) market.
Some of the major companies which are dealing in the next generation sequencing (NGS) are Agilent Technologies, Inc., ThermoFisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., BGI (A subsidiary of BGI Group), Oxford Nanopore Technologies plc, among others domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the next generation sequencing (NGS) market.
For instance,
- In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Europe market and leading to upsurge Company’s growth in the coming years.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the next generation sequencing (NGS) market which also provides the benefit for organization’s profit growth.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON EUROPE NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 U.K.
10.1.4 ITALY
10.1.5 RUSSIA
10.1.6 SPAIN
10.1.7 SWITZERLAND
10.1.8 NETHERLANDS
10.1.9 BELGIUM
10.1.10 TURKEY
10.1.11 REST OF EUROPE
11 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMÉRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.1 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.2 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE
TABLE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 21 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 22 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 23 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 GERMANY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 GERMANY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 34 FRANCE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 35 FRANCE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 36 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 37 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 39 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 U.K. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 U.K. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 46 ITALY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 47 ITALY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 48 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 RUSSIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 53 RUSSIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 SPAINSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 58 SPAIN CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 59 SPAIN SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 63 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 64 SWITZERLAND CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 65 SWITZERLAND SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 NETHERLANDS CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 NETHERLANDS SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 76 BELGIUM CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 77 BELGIUM SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 78 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 79 BRLGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 TURKEY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 83 TURKEY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 86 REST OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING
FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT
FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.
FIGURE 17 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021
FIGURE 18 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021
FIGURE 22 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021
FIGURE 26 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)
FIGURE 30 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)
FIGURE 31 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)
FIGURE 34 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
